Connor, Clark & Lunn Investment Management (CC&L)
KERX

Connor, Clark & Lunn Investment Management (CC&L)’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-121,499
Closed -$2.29M – 681
2014
Q1 		$2.29M Sell
121,499
-12,201
-9% -$184K 0.02% 262
2013
Q4 		$1.84M Sell
133,700
-12,100
-8% -$145K 0.01% 275
2013
Q3 		$1.51M Buy
+145,800
New +$1.3M 0.01% 226

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KERX Position: Q2 2014 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2014, closing a stake of 121,499 shares — an estimated $2.29M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KERX in Q3 2013 and held it in 3 quarters. The position peaked at $2.29M in Q1 2014. 135 funds tracked by Wall St. Rank hold KERX as of Q2 2014.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 121,499 Keryx Biopharmaceuticals Inc shares in Q2 2014, an estimated $2.29M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Keryx Biopharmaceuticals Inc position peaked at $2.29M in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2014.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2014, filed 14 Aug 2014.